Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe...

Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma First development-stage asset to be added to the Essential Pharma...

Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Essential Pharma acquires European rights to Colobreathe®(colistimethate sodium) from Teva Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in...

Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Essential Pharma appoints Lee Morley as Non-Executive Director to the Board Zug, Switzerland & Egham, UK – 21 June 2023 – Essential Pharma, an international specialty pharma group focused on...

Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer Zug, Switzerland & Egham, UK – 24 May 2023 – Essential Pharma, an international specialty pharma company...